23/07/2024 - 15:31

Radiopharm gets crucial nod for brain cancer imaging trial

23/07/2024 - 15:31

Bookmark

Save articles for future reference.

Radiopharm Theranostics has been given the nod of approval by the United States Food and Drug Authority to use its brain cancer-fighting technology in late-stage trials, with a first patient expected to be dosed later this year. The company’s “F18-Pivalate” agent is designed to seek out and define a fatty acid that is overexpressed in brain tumours, but not in normal cells.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options